Effects of cold and warm water bathing of hemiplegic lower limb on its isokinetic muscle strength were studied in 12 chronic stroke patients (9 males and 3 females, 53.3±14.2 yo, Ueda's grading 8.5±1.6 Grade).
Measurements of the isokinetic muscle strength of the knee flexion/extension were repeated three times; 1) after sitting for 10min at room temperature (21-22°C) as a control, 2) after cold water bathing (18°C) of hemiplegic lower limb for 5min, 3) after warm water bathing (41°C, 700ppm artificial CO₂ bath) of hemiplegic lower limb for 10min. The measurements were performed, using Cybex 6000 (Cybex international Co) at velocities of 60, 120, 180 and 240°/sec. Artificial CO₂ bath was prepared by dissolving Kao Babu (Kao Co) in 41°C warm water.
Peak torque of the knee flexions at any velocity decreased significantly after cold water bathing and imcreased after warm water bathing. Change in the maximum power and total work were similar to that of the peak torque. The muscle strength of the knee extension were not changed by neither cold nor warm water bathing.
The correlation coefficient between Ueda's Grade and its isokinetic muscle strength ranged from 0.3 to 0.6 and significantly improved after warm water bathing at velocity of 120 (°/second) in flexion. Warm water bathing might make it easy to exert their muscle strength at 120°/sec in flexion corresponding to their severity of their hemiplegia.
Regarding to the influence of spasticity, patients with no ankle clonus or pseudoclonus showed a tendency to increase in muscle strength of flexion and extension after warm water bathing. In patients with evident clonus, a tendency to decrease on extension and increase on flexion was seen after warm water bathing.
Further studies on the effects of warm water bathing of partial and full immersion in the treatment for spasticity of hemiplegic limb would contribute to stroke rehabilitation.

The purpose of this research was to study the effects of exercise program participation on the personal factors of exercise adherence promotion in the middle-aged and elderly by comparing a group and individual exercise program. The personal factors for promoting exercise adherence, the four domains (i, e. initiative attitude, achievement satisfaction, self-recognition, and intrinsic motivation), were hypothesized. Two groups of middle-aged and elderly subjects, who volunteered to participate in different 6-month exercise programs, were examined. Group 1, 33 subjects (aged 67.7 ±4.3 years : mean±SD), participated in a program consisting of an individual exercise program (combination of endurance and resistance exercise, e. g. cycling exercise, dumbbell and machine exercise, once a week) and group exercise program (e, g. dance and ball game, once a week) . Group 2, 27 subjects (aged 65.2±4.Ovears), participated in the same individual exercise program twice a week. After the 6-month exercise program, significant improvements in group 1 were found in the selfassessment of activity score of the initiative attitude domain, the achievement satisfaction score including enjoyment, achievement and satisfaction, and the self-recognition score representing competence. In group 2, the mastery score in the intrinsic motivation domain was reduced, and the curiosity score in the same domain and the achievement score in the achievement satisfaction domain tended to decrease. These results show that a group program might have a more significant effect on the personal factors hypothesized to promote exercise adherence in this study. Hut there should be follow-up study on the subjects to determine the effectiveness of the program over the long term.

Background/Aims: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS. Methods: Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6. Results: Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population. Conclusions The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.